Corporate / M&A

addex Therapeutics

Homburger News

202303405_Addex

On April 5, 2023, allosteric modulation company Addex Therapeutics Ltd in Plan-les-Ouates, Geneva (SIX: ADXN) announced that it has completed an equity financing transaction with a healthcare-focused institutional investor, pursuant to which Addex agreed to sell 7,999,998 shares in the form of 1,333,333 American Depositary Shares («ADSs») at a gross purchase price of USD 0.95 per ADS, which is equivalent to CHF 0.145 per share. Each ADS represents six shares. Additionally, Addex has issued to the investor ordinary warrants to purchase up to 5,263,158 ADSs, as well as pre-funded warrants to purchase up to 3,929,825 ADSs in a concurrent private placement.
Addex also entered into warrant repricing transactions with the investor, according to which the terms of previously issued warrants were amended, reducing in particular their exercise prices to USD 1 per ADS.
The gross proceeds to Addex, before deducting offering expenses, are USD 5 m. Addex intends to use the net proceeds from this offering to advance its portfolio of drug candidates and for general corporate purposes.
Homburger advised Addex in this transaction. The Homburger team comprised Frank Gerhard and Romain Fakhoury (both Corporate / M&amp;A).

Homburger advised Addex Therapeutics Ltd on new PIPE transaction

Capital Markets

Santhera

On February 28, 2023, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced a private placement of shares and an amendment of its existing financing with funds managed by Highbridge Capital Management, LLC, to provide up to CHF 22.2 m in aggregate, subject to certain milestones and conditions. In addition, Santhera issued 40 m shares in an ordinary capital increase, 37 m of which will be held in treasury for the time being.
The Homburger team was led by Daniel Häusermann (Corporate / M&amp;A, Capital Markets) and included Eduard De Zordi (Capital Markets), Stefan Oesterhelt (Tax), Jasmin Künzle and Romain Fakhoury (both Corporate / M&amp;A, Capital Markets), as well as Anna Delia Lohmann and Fabio Anceschi (both Corporate / M&amp;A).

Homburger advised Santhera on its financing through a private placement of shares and upsizing of existing financing

Employment and Executive Compensation

IP / IT

On February 17, 2023, the controlling shareholder of Reuge SA, the renowned music box producer, successfully completed the sale of a majority stake in the Reuge manufacture to the Swiss luxury watchmaker De Bethune SA.
Homburger advised the controlling shareholder of Reuge SA in this transaction. The Homburger team was led by Frank Gerhard and comprised Romain Fakhoury, Isabelle Cordey, Pepe Hünerwadel (all Corporate / M&amp;A), Laetitia Fracheboud, Ombeline Hischier (both Tax), Jeremy Reichlin (Employment and Executive Compensation), Gregor Bühler and Kristina Martinovic (both IP / IT).

Romain
Fakhoury

Homburger advised Addex Therapeutics Ltd on new PIPE transaction

Homburger advised Santhera on its financing through a private placement of shares and upsizing of existing financing

Homburger advised the controlling shareholder of Reuge on its sale of a majority stake to De Bethune

Join the Team

Romain Fakhoury

Career

Languages

Bar Registration

Teams

RomainFakhoury

Homburger advised Addex Therapeutics Ltd on new PIPE transaction

Homburger advised Santhera on its financing through a private placement of shares and upsizing of existing financing

Homburger advised the controlling shareholder of Reuge on its sale of a majority stake to De Bethune

Join the Team

Romain Fakhoury

Career

Languages

Bar Registration

Teams

Romain
Fakhoury